1 / 7

Purpose

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative. Purpose

hannah-ellis
Download Presentation

Purpose

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHARM-Alternative:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative Purpose To determine whether the angiotensin II receptor blocker candesartan is beneficial in patients with chronic heart failure (CHF) who are intolerant to angiotensin converting enzyme (ACE) inhibitors Reference Granger CB, McMurray JJV, Yusuf S, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6.

  2. CHARM-Alternative:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative- TRIAL DESIGN - Design Multicenter, multinational, randomized, double-blind, placebo-controlled Patients 2028 patients aged >18 years with symptomatic CHF (NYHA class II–IV) and left ventricular ejection fraction <40%, who were not receiving ACE inhibitors because of previous intolerance due to cough (72%), hypotension (13%), renal dysfunction (12%), angioedema or anaphylaxis (4%), or other reasons Follow up and primary endpoint Primary endpoint: cardiovascular death or hospital admission for CHF. Median 33.7 months follow up. Treatment Placebo or candesartan titrated to 32 mg once daily

  3. Candesartan Candesartan Placebo Placebo (n=1015) (n=1013) (n=1015) (n=1013) 66.3 66.8 61 62 68 68 55 55 23 25 47 48 59 57 48 49 40 43 4 4 130.3 129.9 74 70 67 70 12 14 20 13 10 19 7 4 4 6 CHARM-Alternative:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative- TRIAL DESIGN - Baseline characteristics (%) Age (years)a History of MI Male Medications Beta-blocker NYHA class: Spironolactone II Aspirin III Lipid-lowering drug IV Reason for Systolic BP (mmHg)a intolerance Heart failure cause Cough Ischemic Hypotension Idiopathic Renal dysfunction Hypertensive Angioedema/anaphylaxis aMean Granger et al.Lancet 2003;362:772–6.

  4. CHARM-Alternative:Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative- RESULTS - • Primary outcome of cardiovascular death or hospital admission for CHF significantly reduced in candesartan group compared with placebo (33.0 vs. 40.0%, hazard ratio 0.77, 95% CI 0.67–0.89, P=0.0004): each component was reduced but cardiovascular death nonsignificantly • Secondary outcomes – composites of primary outcome and MI, nonfatal stroke and coronary revascularization – also significantly reduced • All-cause mortality not significantly different (26.2 vs. 29.2%, hazard ratio 0.87, 95% CI 0.74–1.03, P=0.11) • Permanent discontinuation similar for candesartan and placebo (30 vs. 29%, P=0.53)

  5. Hazard ratio 0.77 (95% CI 0.67–0.89) P = 0.0004 Placebo Candesartan CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative- RESULTS continued - Cardiovascular death or hospital admission for CHF Proportion 50 with event (%) 40 30 20 10 0 0 1 2 3 3.5 Years after randomization Granger et al.Lancet 2003;362:772–6.

  6. Cardiovascular death 252 (24.8) 219 (21.6) 0.85 (0.71–1.02) 0.072 Hospital admission for CHF 286 (28.2) 207 (20.4) 0.68 (0.57–0.81) < 0.0001 Cardiovascular death, hospital 420 (41.4) 353 (34.8) 0.78 (0.68–0.90) 0.0007 admission for CHF, or MI Cardiovascular death, hospital 432 (42.6) 369 (36.4) 0.80 (0.69–0.91) 0.001 admission for CHF, MI, or stroke Cardiovascular death, hospital 456 (44.9) 396 (39.1) 0.81 (0.71–0.92) 0.002 admission for CHF, MI, stroke, or coronary revascularization CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity -Alternative- RESULTS continued - Primary and secondary outcomes Placebo Candesartan Hazard ratio (n=1015) (n=1013) P (95% CI) No. (%) No. (%) Cardiovascular death or 406 (40.0) 334 (33.0) 0.77 (0.67–0.89) 0.0004 hospital admission for CHF Granger et al.Lancet 2003;362:772–6.

  7. CHARM-Alternative:Candesartan in Heart failure: Assessment ofReduction in Mortality and morbidity -Alternative- SUMMARY - In patients with symptomatic CHF and intolerant to ACE inhibitors, candesartan reduced: • Cardiovascular death or hospitalization for CHF • Secondary outcomes that combined these with MI, stroke and coronary revascularization procedures Despite prior intolerance to another inhibitor of the renin-angiotensin-aldosterone system, candesartan was well tolerated in this patient group

More Related